Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2021-04-12
Clinical Trial Update: Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) [Phase 2]
Phase 2 study evaluating PDR001 in advanced or metastatic well-differentiated non-functional neuroendocrine tumors and poorly differentiated…